Recorded March 6, 2024 | On-Demand Webinar
Access to recordings of virtual introductory courses is limited to one year from the date of purchase as we update programs annually.
Understand background and definitions of biologic and biosimilar drugs and new drug applications (NDAs) and biologics license applications (BLAs). Summarize biosimilar pathways to market and application contents. Learn about the types of meetings available to interact with FDA. Examine interchangeability standards and conditions of use.
This session was recorded as part of FDLI’s virtual course, "Introduction to Biological Products, Including Vaccines, Biosimilars, Cell and Gene Therapies, and Other Advanced Therapies" in March 2024.